Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages

Abstract

Aim To evaluate the cost-effectiveness of therapeutic strategies initiated at different stages of liver fibrosis using three direct-acting antivirals (DAAs), sofosbuvir-ledipasvir (SL), glecaprevir-pibrentasvir (GP), and elbasvir plus grazoprevir (E/G), for Japanese patients with chronic hepatitis C (CHC) genotype 1. Methods We created an analytical decision model reflecting the progression of liver fibrosis stages to evaluate the cost-effectiveness of alternative therapeutic strategies applied at different fibrosis stages. We compared six treatment strategies: treating all patients regardless of fibrosis stage (TA), treating individual patients with one of four treatments starting at four respective stages of liver fibrosis progression (F1S: withholding treatment at stage F0 and starting treatment from stage F1 or higher, and three successive options, F2S, F3S, and F4S), and administering no antiviral treatment (NoRx). We adopted a lifetime horizon and Japanese health insurance payers’ perspective. Results The base case analysis showed that the incremental quality-adjusted life years (QALY) gain of TA by SL, GP, and E/G compared with the strategies of starting treatments for patients with the advanced fibrosis stage, F2S, varied from 0.32 to 0.33, and the incremental cost-effectiveness ratios (ICERs) were US$24,320, US$18,160 and US$17,410 per QALY, respectively. On the cost-effectiveness acceptability curve, TA was most likely to be cost-effective, with the three DAAs at the willingness to pay thresholds of US$50,000. Conclusions Our results suggested that administration of DAA treatment for all Japanese patients with genotype 1 CHC regardless of their liver fibrosis stage would be cost-effective under ordinary conditions.

Global Elimination of HCV—Why Is Poland Still So Far from the Goal?

“…Based on a model reflecting the progression of liver fibrosis and the assessment of the profitability of therapeutic strategies at different stages of fibrosis, and based on comparable analysis from the United States, Suenaga formed the conclusion that the current Japanese recommendations should allow to administer DAA treatment to all those infected with genotype 1 (GT1) regardless of the level of fibrosis. This solution would be the most cost-effective [ 17 ].…”

“…In the analysis of the total number of unmodifiable risk factors of HCV infection (questions R 14,15,17,18,19,20,21,22), two or three factors were reported by more than 60% of respondents (Supplementary Materials Table S2). Similarly to the entire group of respondents, breaking of tissue continuity and hospitalization were the most frequently reported factors occurring in 80.7% and 71.5% of respondents respectively.…”

In vitro Antiviral Activity of Remdesivir Against SARS-CoV-2 and its Variants

“…Currently, antiviral therapy that can be administered early after diagnosis and therapy to improve outcomes are provided to patients at risk of developing a severe form of the disease (9). These treatments are divided into direct-acting antivirals (DAAs) and host-targeting agents (HTAs), where DAAs target a component of the virus and inhibit its replication (10) and HTAs comprises many host factors involved in not only regulation of inflammatory responses but also viral replication, gene expression, assembly, and exit (11,12).…”